trending Market Intelligence /marketintelligence/en/news-insights/trending/BTK6gMtP7WoZFJsQQ3a_Mg2 content esgSubNav
In This List

Arena Pharmaceuticals heart failure drug APD418 gets fast-track tag from US FDA

Blog

Funding Social and Affordable Housing: A Credit Perspective

Blog

Global Capital Markets & SPAC Activity – H1 2021

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals


Arena Pharmaceuticals heart failure drug APD418 gets fast-track tag from US FDA

Arena Pharmaceuticals Inc.'s heart failure therapy APD418 received the U.S. Food and Drug Administration's fast-track designation.

The designation gives regulatory priority to treatments that show promise and offers incentives such as more frequent communication with the regulator and the opportunity to apply for accelerated approval and priority review.

San Diego-based Arena's therapy treats the sudden worsening of heart failure symptoms, referred to as decompensated heart failure. APD418 is being tested in an early-stage clinical trial.